The purpose of this study is to achieving a six-month progression free survival (PFS) of patients receiving autologous dendritic cell vaccine (ADKV) loaded with allogeneic tumor lysate expression of cancer-testis antigens (CTA) in patients with soft tissue sarcomas

Vaccination is carried out on the planned days ± 3 days

1. All examinations must be performed before the vaccine is administered.

   • Full physical examination.
   • Assessment of vital signs (blood pressure, temperature, heart rate), the general condition of the patient and physical activity.
   • Evaluation of concomitant therapy.
   • Assessment of vital signs.
   • Laboratory safety and immunological indicators
   • Assessment of adverse events, symptoms and syndromes of the disease.

2. Introduction of CV in accordance with the dose determined for a given vaccination (see section 9.2. - procedures for delivery and use)

3. After administration, patients are observed for at least 1 hour. An assessment of vital indicators. Undesirable effects detected at the introduction are recorded.

Inclusion Criteria:

• age of 18 or older
• ECOG performance score 0 or 1
• Histologically proven soft tissue sarcoma
• Unresectable or metastatic soft tissue sarcoma
• Ability to give written informed consent
• Objective measured and measurable tumor lesions
• The failure of standard therapy
• Adequate amount of material for genetic research
• No active or chronic infection with HIV, Hepatitis B or Hepatitis C
• Men/Women of childbearing potential must use adequate contraception
• Hematology, liver function and renal function lab tests within required parameters

Exclusion Criteria:

• Untreated or uncontrolled brain metastases.
• History of other active malignancy within last 2 years, except adequately treated other soft tissue sarcoma.
• Autoimmune disease (vitiligo is not a basis for exclusion).
• Serious uncontrolled medical disorder or active infection that would impede treatment.
• Underlying medical or psychiatric condition that would cause administration vaccine
• Any non-oncology vaccine therapy up to 1 month before or after any dose of vaccine
• Concomitant therapy with IL-2, interferon, other non-study immunotherapy, or cytotoxic chemotherapy; immune-suppressive agents within 30 days of registration; other investigational therapies; chronic use of systemic corticosteroids (however, a low stable dose steroid for mild brain edema or adrenal insufficiency is allowed; topical and inhaled standard dose corticosteroids are allowed).
• Dementia or significantly altered mental status that would prohibit understanding or rendering of informed consent and compliance with protocol requirements.
• Pregnant or breastfeeding women.
• Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g. infectious) illness.